A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 11, 2015, Pages 1240-1247

  Magdalinou, Nadia K ^a   Paterson, R W ^b   Schott, J M ^b   Fox, N C ^b   Mummery, C ^b   Blennow, K ^c   Bhatia, K ^b   Morris, H R ^d   Giunti, P ^b   Warner, T T ^a   De Silva, R ^a   Lees, A J ^a   Zetterberg, H ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; PHOSPHOPROTEIN; PROTEIN; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; SOLUBLE AMYLOID PRECURSOR PROTEIN BETA; TAU PROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN; NERVE PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; ATYPICAL PARKINSONIAN SYNDROME; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEMENTIA; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARKINSON DISEASE; PARKINSONISM; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; SHY DRAGER SYNDROME; AGED; CEREBROSPINAL FLUID; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; PATHOLOGY; SUPRANUCLEAR PALSY, PROGRESSIVE;

AGED; BIOMARKERS; COHORT STUDIES; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROSPECTIVE STUDIES; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84947036320     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309562     Document Type: Article

References (40)

1. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
2. Fahn S. Secondary Parkinsonism. Scientic Approaches Clin Neurol 1977;1159-89.
3. Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010;133:2045-57.
4. Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 2012;26:841-70.
5. Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 2014;85:1065-75.
6. Hall S. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445.
7. Bech S, Hjermind LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 2012;18:69-72.
8. Zetterberg H, Petzold M, Magdalinou N. Cerebrospinal fluid alpha-synuclein levels in Parkinson's disease - changed or unchanged? Eur J Neurol 2014;21:365-7.
9. Johansen JS, Williamson MK, Rice JS, et al. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
10. Bonneh-Barkay D, Bissel SJ, Wang G, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008;173:130-43.
11. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol 2010;3:226-37.
12. Hickman SE, El Khoury J. Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010;9:168-73.
13. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
14. Bak TH, Hodges JR, Thomas HB. Corticobasal degeneration: clinical aspects. In: Duyckaerts C, Litvan I, eds. Handbook of clinical neurology. vol. 89. Amsterdam: Elsevier, 2008:509-21.
15. Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. In: Neurology. 2008:670-6.
16. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
17. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-18.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
19. Disease, M.D.S.T.F.o.R.S.f.P.a.s. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-50.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
21. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552-65.
22. Schmidt KS, Mattis P, Adams J, et al. Alternate-form reliability of the Dementia Rating Scale-2. Arch Clin Neuropsychol 2005;20:435-41.
23. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995;45:486-90.
24. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
25. Constantinescu R, Rosengren L, Johnels B, et al. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinsons disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 2010;16:142-5.
26. Abdo WF, Bloem BR, Van Geel WJ, et al. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007;28:742-7.
27. Hughes AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(Pt 4):861-70.
28. Litvan I. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937-44.
29. Wenning GK, Ben-Shlomo Y, Magalhaes M, et al. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-6.
30. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118(Pt 3):759-70.
31. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46:922-30.
32. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-40.
33. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-80.
34. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-6.
35. Hong Z, Shi M, Chung KA, et al. DJ-1 and -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-26.
36. Ohrfelt A, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009;450:332-5.
37. Borghi R, Marchese R, Negro A, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000;287:65-7.
38. Olsson B, Constantinescu R, Holmberg B, et al. The glial marker YKL-40 is decreased in synucleinopathies. Mov Disord 2013;28:1882-5.
39. Luk C, Magdalinou Y, Martí MJ, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012;123:396-405.
40. Massey LA, Jager HR, Paviour DC, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013;80:1856-61.